| Dr Eduardo Uribe, MD | |
|
2222 Benwood St, Harlingen, TX 78550-8532 | |
| (956) 389-2440 | |
| (956) 389-2444 |
| Full Name | Dr Eduardo Uribe |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 25 Years |
| Location | 2222 Benwood St, Harlingen, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215201132 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | P6741 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vhs Harlingen Hospital Company Llc | Harlingen, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bhs Physicians Network Inc | 7315019593 | 585 |
News Archive
A collaborative research team led by scientists at Houston Methodist is one step closer to developing technologies that could help mend broken bones faster. The Department of Defense awarded close to $6 million to the Houston Methodist Research Institute for an initiative aimed at studying two new materials to repair complex fractures in long bones.
Neuronetics, Inc., the established market leader in transcranial magnetic stimulation (TMS) technology, announced today the completion of its Series F Financing Round, which included investment from GE Ventures, as well as its original investor base totaling $34.3 million.
ImmusanT, Inc., a clinical-stage company developing Nexvax2, a therapeutic vaccine intended to protect against the effects of gluten exposure while maintaining a gluten-free diet in HLA-DQ2.5+ patients with celiac disease, today announced the publication of positive data from two Phase 1 clinical trials of Nexvax2 in celiac disease.
Producing more healthcare providers is often touted as the principle solution to the looming shortage in the primary care workforce. A quicker and less costly approach to offset primary care physician shortages can occur with the workforce already in place, through efforts to reduce the widespread waste and inefficiency in the typical physician workday.
› Verified 3 days ago
| Entity Name | Harlingen Physician Network Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699726653 PECOS PAC ID: 1052212123 Enrollment ID: O20040120000931 |
News Archive
A collaborative research team led by scientists at Houston Methodist is one step closer to developing technologies that could help mend broken bones faster. The Department of Defense awarded close to $6 million to the Houston Methodist Research Institute for an initiative aimed at studying two new materials to repair complex fractures in long bones.
Neuronetics, Inc., the established market leader in transcranial magnetic stimulation (TMS) technology, announced today the completion of its Series F Financing Round, which included investment from GE Ventures, as well as its original investor base totaling $34.3 million.
ImmusanT, Inc., a clinical-stage company developing Nexvax2, a therapeutic vaccine intended to protect against the effects of gluten exposure while maintaining a gluten-free diet in HLA-DQ2.5+ patients with celiac disease, today announced the publication of positive data from two Phase 1 clinical trials of Nexvax2 in celiac disease.
Producing more healthcare providers is often touted as the principle solution to the looming shortage in the primary care workforce. A quicker and less costly approach to offset primary care physician shortages can occur with the workforce already in place, through efforts to reduce the widespread waste and inefficiency in the typical physician workday.
› Verified 3 days ago
| Entity Name | Bhs Physicians Network Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598958431 PECOS PAC ID: 7315019593 Enrollment ID: O20080703000069 |
News Archive
A collaborative research team led by scientists at Houston Methodist is one step closer to developing technologies that could help mend broken bones faster. The Department of Defense awarded close to $6 million to the Houston Methodist Research Institute for an initiative aimed at studying two new materials to repair complex fractures in long bones.
Neuronetics, Inc., the established market leader in transcranial magnetic stimulation (TMS) technology, announced today the completion of its Series F Financing Round, which included investment from GE Ventures, as well as its original investor base totaling $34.3 million.
ImmusanT, Inc., a clinical-stage company developing Nexvax2, a therapeutic vaccine intended to protect against the effects of gluten exposure while maintaining a gluten-free diet in HLA-DQ2.5+ patients with celiac disease, today announced the publication of positive data from two Phase 1 clinical trials of Nexvax2 in celiac disease.
Producing more healthcare providers is often touted as the principle solution to the looming shortage in the primary care workforce. A quicker and less costly approach to offset primary care physician shortages can occur with the workforce already in place, through efforts to reduce the widespread waste and inefficiency in the typical physician workday.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Eduardo Uribe, MD 2222 Benwood St, Harlingen, TX 78550-8532 Ph: (956) 389-2440 | Dr Eduardo Uribe, MD 2222 Benwood St, Harlingen, TX 78550-8532 Ph: (956) 389-2440 |
News Archive
A collaborative research team led by scientists at Houston Methodist is one step closer to developing technologies that could help mend broken bones faster. The Department of Defense awarded close to $6 million to the Houston Methodist Research Institute for an initiative aimed at studying two new materials to repair complex fractures in long bones.
Neuronetics, Inc., the established market leader in transcranial magnetic stimulation (TMS) technology, announced today the completion of its Series F Financing Round, which included investment from GE Ventures, as well as its original investor base totaling $34.3 million.
ImmusanT, Inc., a clinical-stage company developing Nexvax2, a therapeutic vaccine intended to protect against the effects of gluten exposure while maintaining a gluten-free diet in HLA-DQ2.5+ patients with celiac disease, today announced the publication of positive data from two Phase 1 clinical trials of Nexvax2 in celiac disease.
Producing more healthcare providers is often touted as the principle solution to the looming shortage in the primary care workforce. A quicker and less costly approach to offset primary care physician shortages can occur with the workforce already in place, through efforts to reduce the widespread waste and inefficiency in the typical physician workday.
› Verified 3 days ago
Jesus Rodriguez, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2222 Benwood St, Harlingen, TX 78550 Phone: 956-389-2448 | |
Bright Ohene Odei, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 707 W Sesame Dr, Harlingen, TX 78550 Phone: 956-423-8042 Fax: 469-893-7810 | |
Erica Ruiz Espinoza, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 707 W Sesame Dr, Harlingen, TX 78550 Phone: 956-423-8042 Fax: 956-423-2907 | |
Mr. Prasad V Movva, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 922 E Tyler Ave, Harlingen, TX 78550 Phone: 956-440-7000 Fax: 956-440-7042 | |
Dr. Jason E Peters, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2106 Hale Avenue, Harlingen, TX 78550 Phone: 956-423-9111 Fax: 956-423-9273 | |
Dr. John Barry Ranelle, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1214 E Bowie Ave, Harlingen, TX 78550 Phone: 956-536-7794 Fax: 956-686-2708 | |
Edward G. Oorjitham, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1205 N Ed Carey Dr, Suite 2c, Harlingen, TX 78550 Phone: 956-440-8020 Fax: 956-440-8131 |